'Distinct' signs of latest Covid-19 Nimbus variant including 'razor blade throat'
The UK has seen a rise in Covid-related hospital admissions by almost 10 per cent in the last week of May
The UK is grappling with the rise of a new Covid strain known as Nimbus or NB. 1.8.1. Britain has seen an increase of almost 10 per cent in Covid-related hospital admissions in the final week of May amid cautions from the World Health Organisation (WHO).
The novel strain is marked by a harrowing "razor blade throat" symptom that mimics the feeling of blades scraping your throat with every swallow — sufferers are urged to seek rest, liquids and pain relief.
Dr Naveed Asif of The London General Practice told the Independent about the unique nature of this sore throat, labelling it "distinctive" for those struck by Nimbus. On top of that, the NHS advises anyone suspecting they've caught Covid to self-isolate.
Echoing NHS guidance, the UKHSA warns: "If you have symptoms of a respiratory infection, such as Covid-19, and you have a high temperature or do not feel well enough to go to work or carry out normal activities, you should avoid contact with vulnerable people and stay at home if possible."
Speaking on the latest Covid symptoms, Doctor Mohamed Imran Lakhi of Prescription Doctor's said: 'People commonly report a severe sore throat, persistent fatigue, mild cough, fever, muscle aches, and nasal congestion.
"Some also experience digestive issues like nausea or diarrhoea, which isn't always typical with Covid variants.'
For those living with Covid and seeking further advice, including when self-isolation isn't viable, visit the Gov.uk website, reports the Mirror.
Initially detected in January, the Nimbus variant has since taken a global stage.
Nimbus has become the prevalent variant in China and constitutes a third of US cases, and is currently energising a fresh uptick in Australian infections.
A recent preprint study suggests that the so-called Nimbus variant of Covid-19 may bind to human cells more effectively, potentially allowing for easier transmission and the ability to dodge immunity from previous infections.
This research on Nimbus is awaiting peer review, but already the World Health Organisation has assured that current vaccines remain potent against this strain.
As reported by Salon, there are no indications that Nimbus is tied to increased illness severity in comparison with other variants.
University of Guelph's Dr. T. Ryan Gregory told Salon: "That said, we learned from Omicron that high transmissibility can cause as much damage as high per infection virulence and at this point it is not just acute severity that is of concern, but longer-term impacts of repeated infection."
Dr. Gregory added that spotting symptoms unique to Nimbus could be tough due to the mixing of various strains and less testing compared to peak pandemic periods.
Furthermore, Dr Gayatri Amirthalingam of UKHSA recently declared: "NB.1.8.1 has been detected in small numbers in the UK to date, but international data suggests that it is growing as a proportion of all Covid cases.
"Based on the available information so far however, there is no evidence to suggest that this variant causes more severe disease than previous variants, or that the vaccines in current use will be less effective against it."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Powys County Times
35 minutes ago
- Powys County Times
Poll suggests support for better end-of-life care over assisted dying Bill
More than two thirds of people feel the assisted dying Bill should be replaced with a plan for better end-of-life care, according to a survey published days ahead of a major vote on the issue. The polling, commissioned by a group opposed to assisted dying being legalised, 'blows apart the arguments that the public are desperate' for a change in the law, a campaigner claimed. Bill sponsor Kim Leadbeater said last week that MPs should not have to choose between supporting assisted dying or palliative care as it is not an 'either/or' conversation for dying people. She said palliative care and assisted dying 'can and do work side by side to give terminally-ill patients the care and choice they deserve in their final days', and urged MPs to support 'all options available to terminally ill people'. An amendment to the Bill, requiring the Health Secretary to publish an assessment of the availability, quality and distribution of palliative and end-of-life care one year after the Bill passing into law, could be voted on on Friday. Friday is also set to be the Terminally Ill Adults (End of Life) Bill's third reading stage, which is likely to see the overall Bill voted on for the first time since November's historic yes vote, when a majority of 55 supported the principle of assisted dying for England and Wales. The latest polling, commissioned by Care Not Killing and carried out by British Polling Council member Whitestone, saw 2,089 UK adults surveyed online between May 30 and June 1. Respondents, who are said to have been weighted to be a representative sample, were told of concerns raised by the Royal Colleges of Physicians and Psychiatrists and the Association for Palliative Medicine about the Bill in its current form as well as opposition from disability campaigners. In this context, they were asked about replacing the Bill with a plan to improve and invest in palliative care – to which 69% agreed, and about a Royal Commission being set up to consider and make recommendations for a holistic end-of-life and palliative care service – with which 61% agreed. Almost two thirds (65%) said the Government's priority should be sorting out palliative and social care before changing the law – down very slightly from 66% last year. Gordon Macdonald, chief executive of Care Not Killing, said: 'This major new poll blows apart the arguments that the public are desperate for a so-called assisted dying law. 'The public want the Government and MPs to focus on fixing the NHS and palliative care which they know are broken. After all one in four Brits who would benefit from palliative care aren't currently receiving it, while in many places services are piecemeal, part-time or facing cuts.' It comes as former prime minister Gordon Brown repeated his opposition to assisted dying. Writing in the Guardian, he said: 'It has become clear that whatever views people hold on the principle, passing the terminally ill adults (end of life) bill into law would privilege the legal right to assisted dying without guaranteeing anything approaching an equivalent right to high-quality palliative care for those close to death.' He said MP's personal preferences 'cannot be separated off from the duties they have as members of a community to ensure that the way we treat the dying reflects the values of a decent, compassionate country'. He added: 'That should mean upholding the role of the medical professions as care-givers, and exclusively care-givers; avoiding the possibility of private profiteering by legal-medical consortiums which might well commercialise assisted dying as a lucrative business; safeguarding vulnerable people about whose fate the royal medical colleges have all expressed concern; preventing unacceptable coercive pressures that can be brought to bear on disabled people, and those who are incapacitated or mentally stressed; and thus showing that as a society we value life above death.' Dozens of Labour MPs called for Friday's overall vote to be delayed, asking for more time to scrutinise a Bill they brand as 'perhaps the most consequential piece of legislation that has appeared before the House in generations'. Writing to Commons leader Lucy Powell, they said: 'We implore you as the Leader of the House to allocate more Parliamentary time to the scrutiny of this Bill, the valid concerns that members have about its implementation, and the consequences it could have on vulnerable populations.' A Government spokesperson said: 'This Bill has been brought as a Private Members' Bill. The amount of time for debate is therefore a matter for the House.' The Bill's sponsor, Labour MP Kim Leadbeater, has repeatedly stated that her proposed legislation has been strengthened since it was first introduced last year, insisting it is subject to robust safeguards. Medical staff are among some of the MPs who back the Bill. As it stands, the proposed legislation would allow terminally-ill adults in England and Wales, with fewer than six months to live, to apply for an assisted death, subject to approval by two doctors and a panel featuring a social worker, senior legal figure and psychiatrist. MPs are entitled to have a free vote on the Bill and any amendments, meaning they decide according to their conscience rather than along party lines. Prime Minister Sir Keir Starmer voted in favour of the Bill last year, but said the Government remains neutral on the issue.
South Wales Argus
36 minutes ago
- South Wales Argus
Genetic testing study to boost medication response starts in Glasgow
The landmark trial will recruit up to 4,000 patients over the next two years in the NHS Greater Glasgow and Clyde area, to investigate how an individual's genetic profile affects their response to 60 common medications. It is hoped the Phoenix Study will to lead to wider implementation of genetic testing across Scotland, making 'precision medicine' routine, for the first time. Researchers hope it will pave the way for tailored prescribing across cardiology, stroke, surgery, orthopaedics, geriatrics, gynaecology, ENT, rheumatology, respiratory, neurology, psychiatry and other specialities. The trial will take place at the Queen Elizabeth University Hospital (QEUH) in Glasgow. Pharmacogenomics (PGx) – the study of how genes influence individual responses to drugs – has not been routinely used in clinical practice in the UK, amid hopes evidence will lead to change. Genetic test results will be sent to clinicians, allowing for treatment decisions to be adjusted, and patients will be followed up regularly to monitor the effects of any changes, to ensure they receive the highest standard of care. The trial is due to test 'precision medicine' for the first time in the UK (Julien Behal/PA) Patients will undergo a simple genetic test to analyse their DNA and the results, returned within days, will help doctors determine whether each patient is receiving the most suitable drug and dosage based on their genetic make-up. Around 15% are expected to carry genetic variants that may reduce the effectiveness of a medication or increase the risk of side-effects. In some cases, the prescribed drug may be ineffective, or a different dosage may be needed. The trial is open to adult in-patients in the QEUH and patients will be randomly assigned to either receive the pharmacogenomic test immediately, or at three months, which will allow the researchers to establish evidence of benefit. Without prior testing, these issues can go unnoticed, often leading to a trial-and-error approach to treatment, according to researchers. It is led by Sandosh Padmanabhan, Pontecorvo chair of Pharmacogenomics at the University of Glasgow, in partnership with the University of Glasgow's Living Laboratory, the NHSGGC-hosted West of Scotland Innovation Hub, and industry partners MyDNA and Agena Bioscience. Patient Eric Balish was asked to take part by consultants, after having a heart attack and subsequent surgery. He was immediately prescribed clopidogrel, one of the 60 drugs included in the study, but has since had his medication changed a number of times. Mr Balish said: 'I knew a bit about personalised medicine previously, and so when I was asked to take part in the Phoenix Study I was happy to do it. 'If you're asked to participate and support long-term research like this, then it's no great hardship to give something back and just do the right thing. I am hopeful my information can be of use to the trial and in the future.' Prof Padmanabhan, a consultant at the QEUH, said: 'Physicians and pharmacists increasingly recognise that PGx-informed prescribing and dispensing improves both the efficacy and safety of drug treatment. 'The primary goal of this trial is to evaluate the clinical and health-economic impact of PGx-guided prescribing. 'Specifically, we want to determine if a PGx-guided approach to prescribing can significantly reduce the incidence and severity of drug related side-effects and/or treatment failures. 'This evaluation will compare the outcomes of participants who receive PGx-guided medication management to those receiving standard care.' Dr Katriona Brooksbank, research and innovation lead for NHSGGC and the West of Scotland Innovation Hub, said: 'We are incredibly excited to be supporting this trial, which could have a major impact on the treatments patients are prescribed based on their own genetics. 'It will put precision medicine into action as researchers look to determine how a person's own genetic make-up can affect the drugs they are given as treatments. 'This could allow clinicians to reduce adverse reactions and side effects, ensuring the best possible outcomes for patients.' Allan Sheffield, co-founder of MyDNA, said: 'For MyDNA, the Phoenix Study embodies the future of healthcare. 'Our unique combination of pharmacogenomic clinical decision support and in-house Gene by Gene accredited testing empowers clinicians to move beyond guesswork. 'This trial will demonstrate the profound impact of precision medicine, paving the way for a future where this approach routinely drives better patient outcomes.'
Glasgow Times
37 minutes ago
- Glasgow Times
Genetic testing study to boost medication response starts in Glasgow
The landmark trial will recruit up to 4,000 patients over the next two years in the NHS Greater Glasgow and Clyde area, to investigate how an individual's genetic profile affects their response to 60 common medications. It is hoped the Phoenix Study will to lead to wider implementation of genetic testing across Scotland, making 'precision medicine' routine, for the first time. Researchers hope it will pave the way for tailored prescribing across cardiology, stroke, surgery, orthopaedics, geriatrics, gynaecology, ENT, rheumatology, respiratory, neurology, psychiatry and other specialities. The trial will take place at the Queen Elizabeth University Hospital (QEUH) in Glasgow. Pharmacogenomics (PGx) – the study of how genes influence individual responses to drugs – has not been routinely used in clinical practice in the UK, amid hopes evidence will lead to change. Genetic test results will be sent to clinicians, allowing for treatment decisions to be adjusted, and patients will be followed up regularly to monitor the effects of any changes, to ensure they receive the highest standard of care. The trial is due to test 'precision medicine' for the first time in the UK (Julien Behal/PA) Patients will undergo a simple genetic test to analyse their DNA and the results, returned within days, will help doctors determine whether each patient is receiving the most suitable drug and dosage based on their genetic make-up. Around 15% are expected to carry genetic variants that may reduce the effectiveness of a medication or increase the risk of side-effects. In some cases, the prescribed drug may be ineffective, or a different dosage may be needed. The trial is open to adult in-patients in the QEUH and patients will be randomly assigned to either receive the pharmacogenomic test immediately, or at three months, which will allow the researchers to establish evidence of benefit. Without prior testing, these issues can go unnoticed, often leading to a trial-and-error approach to treatment, according to researchers. It is led by Sandosh Padmanabhan, Pontecorvo chair of Pharmacogenomics at the University of Glasgow, in partnership with the University of Glasgow's Living Laboratory, the NHSGGC-hosted West of Scotland Innovation Hub, and industry partners MyDNA and Agena Bioscience. Patient Eric Balish was asked to take part by consultants, after having a heart attack and subsequent surgery. He was immediately prescribed clopidogrel, one of the 60 drugs included in the study, but has since had his medication changed a number of times. Mr Balish said: 'I knew a bit about personalised medicine previously, and so when I was asked to take part in the Phoenix Study I was happy to do it. 'If you're asked to participate and support long-term research like this, then it's no great hardship to give something back and just do the right thing. I am hopeful my information can be of use to the trial and in the future.' Prof Padmanabhan, a consultant at the QEUH, said: 'Physicians and pharmacists increasingly recognise that PGx-informed prescribing and dispensing improves both the efficacy and safety of drug treatment. 'The primary goal of this trial is to evaluate the clinical and health-economic impact of PGx-guided prescribing. 'Specifically, we want to determine if a PGx-guided approach to prescribing can significantly reduce the incidence and severity of drug related side-effects and/or treatment failures. 'This evaluation will compare the outcomes of participants who receive PGx-guided medication management to those receiving standard care.' Dr Katriona Brooksbank, research and innovation lead for NHSGGC and the West of Scotland Innovation Hub, said: 'We are incredibly excited to be supporting this trial, which could have a major impact on the treatments patients are prescribed based on their own genetics. 'It will put precision medicine into action as researchers look to determine how a person's own genetic make-up can affect the drugs they are given as treatments. 'This could allow clinicians to reduce adverse reactions and side effects, ensuring the best possible outcomes for patients.' Allan Sheffield, co-founder of MyDNA, said: 'For MyDNA, the Phoenix Study embodies the future of healthcare. 'Our unique combination of pharmacogenomic clinical decision support and in-house Gene by Gene accredited testing empowers clinicians to move beyond guesswork. 'This trial will demonstrate the profound impact of precision medicine, paving the way for a future where this approach routinely drives better patient outcomes.'
